Rapid influenza diagnostic tests (RIDTs) are immunoassays which enable the identification of the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens.
Portland, OR -- (SBWIRE) -- 10/11/2017 -- The Rapid Influenza Diagnostic Test (RIDT) have gained traction over the years owing to the advantages offered by these tests such as quick access to the result in less than approximately 15 minutes, and is easy to perform.The RIDTs are highly utilized in the clinical decision making as the assist in the diagnostic and treatment decisions for patients in clinical settings.
Early buyers will receive 20% customization on this report
Get PDF Brochure of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/4126
The factors that fuel the growth of the global rapid influenza diagnostic tests (RIDTs) market are escalating incidence of influenza, increasing focus in research funding for influenza diagnostics, and rising demand for rapid diagnosis and control of influenza. However, variability in sensitivity as well as specificity among influenza diagnostic tests, along with unstable regulatory framework regrading approval of new diagnostic tests restrain the market growth. Moreover, emerging advanced influenza diagnostics tests in the market is anticipated to offer lucrative opportunities for the expansion of the market.
The market is segmented on the basis of end user, and region. Based on end user, the market is segmented into hospitals & clinics, laboratories, and other. Based on region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key players that operate in the market are Thermo Fisher Scientific, Roche Diagnostics, Alere Inc., Quidel Corporation, Becton, Dickinson and Company, DiaSorin, SA Scientific Ltd., Meridian Bioscience, Inc., Analytik Jena AG (Endress+Hauser AG), and Luminex Corporation.
Rapid Influenza Diagnostic Test (RIDT) Market Key Segments:
By End User
- Hospitals & Clinics